Going home within 24 hours after loop ileostomy reversal: what a 2026 systematic review found — and where the data still has gaps
A May 2026 systematic review in the International Journal of Colorectal Disease pooled data from 12 studies covering 30,040 patients and found no statistically significant increase in serious complications for early discharge after loop ileostomy reversal — but the authors urge caution while better-designed trials catch up.

A May 2026 systematic review in the International Journal of Colorectal Disease pooled data from 12 studies covering 30,040 patients and found no statistically significant increase in serious complications for early discharge after loop ileostomy reversal — but the authors urge caution while better-designed trials catch up.
Sources
Many people in our community live with a loop ileostomy as a temporary arrangement — a stoma created to let a newly formed bowel join heal before the surgeons close it. One of the most common questions we hear from people waiting for their reversal is: what does recovery look like?
A new systematic review has added useful, if cautious, data to that question.
Background: why early discharge is being studied
A loop ileostomy is a type of temporary stoma where part of the small bowel is brought to the surface of the abdomen, allowing digestive waste to bypass a lower bowel join while it heals after surgery. NHS guidance explains that loop ileostomies are typically intended to be reversed — closed — once the surgical team is satisfied that the join is secure.
Reversal has traditionally meant several days in hospital. The reason is straightforward: the three most watched-for complications in the early days after stoma closure are anastomotic leak (a failure of the bowel join), postoperative ileus (the bowel being slow to restart), and wound infection. Standard hospital stays give clinical teams the ability to detect and respond to any of these early.
In recent years, some surgical centres have been trialling much shorter stays — discharging patients within 23 hours, including some same-day discharges — as part of what are called enhanced recovery pathways. The question was whether doing so is safe.
What the systematic review asked — and how it was designed
In May 2026, the International Journal of Colorectal Disease published a systematic review and meta-analysis that set out to pool the available evidence on early discharge after loop ileostomy reversal. The review was conducted in accordance with PRISMA reporting guidelines and was registered prospectively on PROSPERO (registration: CRD420251252408) before the analysis began — both markers of methodological rigour.
The researchers identified 12 studies meeting their criteria: 11 retrospective cohort studies and 1 randomised controlled trial. Together these studies covered 30,040 patients; of those, 2,611 (8.7%) had been managed under an ambulatory or short-stay pathway — that is, discharged within 23 hours of reversal surgery. The remaining 27,429 patients had received standard inpatient admission. (Mulhall et al., Int J Colorectal Dis, May 2026)
What the data showed
For each of the three primary complications — anastomotic leak, postoperative ileus, and surgical site infection — the pooled analysis found no statistically significant difference between the early-discharge group and those who stayed in under standard care:
- Anastomotic leak: pooled odds ratio 1.31 (95% CI 0.24–7.32) — no significant difference
- Postoperative ileus: pooled odds ratio 0.49 (95% CI 0.16–1.55) — no significant difference
- Surgical site infection: pooled odds ratio 0.76 (95% CI 0.38–1.51) — no significant difference
Readmission rates — another important secondary measure — also showed no significant difference between the groups (pooled OR 0.97, 95% CI 0.78–1.19). (Mulhall et al., 2026)
One secondary finding stood out: looking at overall postoperative complications taken together, the early-discharge group showed a modest but statistically significant reduction compared with standard admission (pooled OR 0.70, 95% CI 0.50–0.98). Rates of serious complications — Clavien-Dindo grade III or IV events, which are the ones requiring further surgery or intensive care — and mortality were comparable in both groups. (Mulhall et al., 2026)
What the data cannot yet tell us
Here is where the review's authors are appropriately careful — and where the research is honest about its own limits.
The confidence intervals on the three primary outcomes are wide. For anastomotic leak, the interval runs from 0.24 to 7.32 — which means the true effect could range from a meaningful protective effect to a meaningful harm. As the authors put it, the low event rates and wide CIs "likely preclude confident exclusion of a clinically meaningful effect." That is not a clean bill of safety.
A systematic review draws together the studies that exist; it cannot make those studies larger, more consistent, or better controlled than they were. And in this case, 11 of the 12 studies were retrospective cohort studies — meaning they looked back at patients who had already been treated, rather than randomly assigning people to pathways in real time. Different centres also defined "early discharge" differently: some counted same-day discharge, others set the threshold at 23 hours, and others used "short-stay" without a fixed time limit. That inconsistency in what exactly was being studied is part of why firm conclusions are hard to draw. (Mulhall et al., 2026)
The review authors conclude that early discharge after loop ileostomy reversal, when carried out within a structured perioperative programme and in appropriately selected patients, appears to be safe based on the evidence available today. They do not advocate for widespread adoption. They call for adequately powered, multicentre randomised controlled trials with standardised definitions of "early discharge" and consistent outcome measures before the evidence base is strong enough to recommend broader rollout.
What this means for our community
If you are living with a loop ileostomy and waiting for reversal, the kind of recovery programme your surgical team uses — and whether a short-stay or same-day pathway is an option where you are treated — will depend on your individual clinical situation, your surgeon's judgement, and what is available at your centre.
This research adds to a growing body of early evidence that shorter stays may be safe for selected patients within structured programmes. It does not change what your team should recommend for you specifically, and it is worth asking your surgeon whether an enhanced recovery pathway is something they use and whether your situation might suit it.
Your clinician knows your case best — ask them first.